[{"orgOrder":0,"company":"Menten AI","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Menten AI","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Menten AI \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Menten AI \/ Bristol Myers Squibb"}]

Find Clinical Drug Pipeline Developments & Deals by Menten AI

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AGGSpend
                          Not Confirmed
                          AGGSpend
                          Not Confirmed

                          Details : Under the collaboration, Menten AI and Bristol Myers Squibb leveraged Menten AI’s generative AI platform and team’s expertise to optimize the biochemical properties of certain peptide macrocycles.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          May 28, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery Platform

                          Sponsor : Bristol Myers Squibb

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank